BOLLI NICCOLO'

CURRICULUM VITAE
Prof. Niccolo Bolli

Personal data
Place and date of birth: Perugia, Italy on January 3rd, 1977
Current Job Address:
Department of Oncology and Hemato-oncology, University of Milano
Division of Hematology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via F. Sforza 35, 20122 Milan – Italy (+39 02 5503 3337)
e-mail: niccolo.bolli@unimi.it

Education
2001 Medical Doctor degree, School of Medicine, University of Perugia, Perugia- Italy
2005 National Board of Hematology, School of Medicine, University of Perugia, Perugia- Italy
2010 Ph.D. in Hematology, University of Perugia, Perugia- Italy
2015 Associate Professor of Hematology, University of Milano, Milan, Italy

Major Professional record
̶ 2005-2007 Ph.D. student in the laboratory of Prof. B. Falini, University of Perugia, Perugia- Italy
̶ 2007-2011 Post-Doctoral fellow in the laboratory of Dr. A. Thomas Look, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA, USA.
̶ 2011-2015 Clinical Lecturer at the University of Cambridge, Cambridge, UK.
̶ 2011-present: Visiting scientist at the Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, UK.
̶ 2015-present: Associate Professor of Hematology, University of Milan, Milan, Italy
̶ 2015-present: Consultant in Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Major fields of interest
̶ Molecular pathogenesis of multiple myeloma: i) genomics; ii) prognostic implications of molecular lesions.
̶ Development and applications of NGS-based methods for the detection of mutations, copy number changes and rearrangements in multiple myeloma;
̶ Development and applications of NGS-based methods for the detection of mutations and copy number changes myeloid malignancies;
̶ Use of genomic information for a revised classification of hematopoietic neoplasms;
̶ Study of the pre-cancerous phases of evolution of hematopoietic neoplasms;

Grants awarded on a competitive basis
2019-2024 Consolidator Grant from the European Research Commission (ERC): “spontaneous evolution and clonal heterogeneity in monoclonal gammopathies: from mechanisms of progression to clinical management – BECOMING”. EUR 1'998’781
2016-2018 My First AIRC grant from the Associazione Italiana per la Ricerca sul Cancro. EUR 188’000
2012-2014 EHA fellowship from the European Haematology Association. EUR 72’000
2012-2013 Starter grant for academic clinical lecturers from the Academy of Medical Sciences. GBP 30’000
2009-2011 Leukemia and Lymphoma Society Career Development Program Special Fellow Award. USD 195’000
2007-2009 American-Italian Cancer Foundation (AICF) International Fellowship Award. USD 70'000
2005-2007 Federazione Italiana per la Ricerca sul Cancro (FIRC, Italian Federation for Cancer Research) Fellowship Award. EUR 45’000



Research awards
2013 First prize “Under 40 in Hematology – Giovani ematologi a confronto” promosso dalla Società Italiana di Ematologia. EUR 6’000
2012 Winner of the Young Scientist Award at the 17th meeting of the European Haematology Association with an abstract titled: “Whole Exome Sequencing Defines Clonal Architecture and Genomic Evolution in Multiple Myeloma”. EUR 5000
2011 Winner of a Lady Tata Award for a project titled: “Genetc modifiers of the phenotypic landscape in JAK2V617F myeloproliferative neoplasms”. EUR 12’000
2006 Winner of the “Grazia Caiani Bartocci” prize from the Accademia Anatomico-Chirurgica of the University of Perugia in Mat 2006 with a project titled “Aspetti funzionali delle mutazioni del gene NPM1”. EUR 4.000

Bibliometric indexes (14/01/2020):
Scopus: 76 publications, H-index: 33, total citations: 9229
Web of science: 101 publications, H-index: 32, total citations: 8644
Google scholar: 183 publications, H-index: 41, total citations: 13419

Peer reviewed publications

1. Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep. 2020;12(3).
2. Da Vià MC, Ziccheddu B, Maeda A, et al. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. HemaSphere. 2020;4(6):e502.
3. Vittoria, L, Bozzi F, Capone I, Carniti C, Lorenzini D, Gobbo M, Bolli N, and Aiello A. “A Rare Biclonal Hairy Cell Leukemia Disclosed by an Integrated Diagnostic Approach: A Case Report.” Cytometry Part B: Clinical Cytometry (December 18, 2020). https://doi.org/10.1002/cyto.b.21980.
4. Maura F, Dodero A, Carniti C, et al. CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL- NOS). Haematologica. https://doi.org/10.3324/haematol.2020.262659 [Early view]
5. Rustad, Even H, Venkata D Yellapantula, Dominik Glodzik, Kylee H. et al. Revealing the Impact of Structural Variants in Multiple Myeloma. Blood Cancer Discovery, 2020.
6. Monti, Valentina, Filippo Bagnoli, Niccolò Bolli, Laura Vittoria, Sabine Stioui, Maria Luisa Moiraghi, et al. A New Case of Myelodysplastic Syndrome Associated with t(3;3)(q21;q26) and Inv(11)(p15q22). Tumori Journal, August 24, 2020.
7. Manzoni, Martina, Alessandra Pompa, Sonia Fabris, Francesca Pelizzoni, Gabriella Ciceri, Manuela Seia, Bachisio Ziccheddu, et al. Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. HemaSphere 4, no. 4 (August 2020).
8. Manzoni, Martina, Valentina Marchica, Paola Storti, Bachisio Ziccheddu, Gabriella Sammarelli, Giannalisa Todaro, et al. Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. Cancers 12, no. 5 (May 23, 2020): 1332.
9. D’Agostino, Mattia, Gian Maria Zaccaria, Bachisio Ziccheddu, Even H Rustad, Elisa Genuardi, Andrea Capra, Stefania Oliva, et al. Early Relapse Risk in Newly Diagnosed Multiple Myeloma Patients Characterized by Next-Generation Sequencing. Clinical Cancer Research, July 2, 2020.
10. Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F et al. Timing the initiation of multiple myeloma. Nat Commun 2020;11:1917
11. Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? Front Oncol 2020;10:189
12. Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH et al. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv 2020;4:830-844
13. Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, Demeulemeester J et al. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition Nat Genet 2020;52:306-319
14. Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. JAMA Oncol. 2019.
15. Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. Nature Publishing Group; 2019;9:101–9.
16. Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nature Communications. 2019;10:3835.
17. Rustad EH, Yellapantula V, Bolli N, Leongamornlert D, Nadeu F, Angelopoulos N et al. Timing the Initiation of Multiple Myeloma. SSRN Journal [Internet]. 2019. Available from: https://ssrn.com/abstract=3409453
18. Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L et al. A practical guide for mutational signature analysis in hematological malignancies. Nature Communications. Nature Publishing Group; 2019;10:2969.
19. Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan J, Dodero A et al. Integration of Transcriptional and Mutational Data Simplifies the Stratification of Peripheral T-Cell Lymphoma. Am J Hematol. 2019.
20. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159–70.
21. Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A et al. Genomic patterns of progression in smoldering multiple myeloma. Nature Communications. 2018;9:3363.
22. Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. Nature Publishing Group; 2018;364:1046.
23. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. American Society of Hematology; 2018;:blood–2018–03–840132–24.
24. Collord G, Martincorena I, Young MD, Foroni L, Bolli N, Stratton MR et al. Recurrent histone mutations in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2018.
25. Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018;32:1044–8.
26. Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, De Philippis C et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32:2604–16.
27. Soldarini M, Farina L, Genderini A, Bolli N. A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome. BMJ Case Rep. BMJ Publishing Group Ltd; 2017;2017:bcr–2016–218850.
28. Bolli N, Barcella M, Salvi E, D'Avila F, Vendramin A, De Philippis C et al. Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. Cancer. 2017;123:3701–8.
29. Maura F, Guidetti A, Pellegrinelli A, Dodero A, Pennisi M, Caprioli C et al. High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. Blood Cancer J. 2016;6:e491.
30. Wang M, Zhang S, Chuang S-S, Ashton-Key M, Ochoa E, Bolli N et al. Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. Oncotarget. 2017;8:17763–70.
31. Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49:332–40.
32. Mupo A, Seiler M, Sathiaseelan V, Pance A, Yang Y, Agrawal AA et al. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia. 2016;31:720–7.
33. Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P et al. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 2016;6:e467.
34. De Philippis C, Di Chio MC, Sabattini E, Bolli N. Bowel perforation from occult ileal involvement after diagnosis in a case of primary mediastinal large B-cell lymphoma. BMJ Case Rep. 2016;2016.
35. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374:2209–21.
36. McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JML, Tischler G et al. Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. Blood. 2016;128:e1–9.
37. Grove CS, Bolli N, Manes N, Varela I, Van't Veer M, Bench A et al. Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution. Br J Haematol. 2017;176:825–9.
38. Maura F, Dodero A, Carniti C, Bolli N. Biology of peripheral T cell lymphomas – Not otherwise specified: Is something finally happening? Pathogenesis. Elsevier; 2016;3:9–18.
39. Bolli N, Manes N, McKerrell T, Chi J, Park N, Gundem G et al. Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Haematologica. 2015;100:214–22.
40. Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai Y-T et al. Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014;124:3110–7.
41. Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29:1177–85.
42. Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife. 2014;3.
43. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M et al. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science. American Association for the Advancement of Science; 2014;345:1251343–3.
44. Sportoletti P, Varasano E, Rossi R, Bereshchenko O, Cecchini D, Gionfriddo I et al. The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. Blood. 2013;121:3447–58.
45. Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I, Tubio JMC et al. Processed pseudogenes acquired somatically during cancer development. Nature Communications. 2014;5.
46. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014;46:487–91.
47. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications. 2014;5:2997.
48. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.
49. Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Leukemia. 2013;27:1820–5.
50. Payne EM, Bolli N, Rhodes J, Abdel-Wahab OI, Levine R, Hedvat CV et al. Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood. 2011;118:903–15.
51. Grabher C, Payne EM, Johnston AB, Bolli N, Lechman E, Dick JE et al. Zebrafish microRNA-126 determines hematopoietic cell fate through c-Myb. Leukemia. 2011;25:506–14.
52. Bolli N, Payne EM, Rhodes J, Gjini E, Johnston AB, Guo F et al. cpsf1 is required for definitive HSC survival in zebrafish. Blood. 2011;117:3996–4007.
53. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117:1109–20.
54. Albiero E, Bolli N, Falini B, De Marco MF, Madeo D, Martelli MP et al. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia. 2007;21:2052–4; authorreply2054; discussion2055–6.
55. Falini B, Bigerna B, Pucciarini A, Tiacci E, Mecucci C, Morris SW et al. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. Leukemia. 2006;20:368–71.
56. Bolli N, Payne EM, Grabher C, Lee J-S, Johnston AB, Falini B et al. Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. Blood. 2010;115:3329–40.
57. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23:1731–43.
58. Liso A, Castiglione F, Cappuccio A, Stracci F, Schlenk RF, Amadori S et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 2008;93:1219–26.
59. Martelli MP, Manes N, Pettirossi V, Liso A, Pacini R, Mannucci R et al. Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML. Leukemia. Nature Publishing Group; 2008;22:195–8.
60. Bolli N, Galimberti S, Martelli MP, Tabarrini A, Roti G, Mecucci C et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol. 2006;7:350–2.
61. Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res. American Association for Cancer Research; 2007;67:6230–7.
62. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RAF et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005;19:1760–7.
63. Tiacci E, Orvietani P-L, Bigerna B, Pucciarini A, Corthals GL, Pettirossi V et al. Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. Blood. 2005;105:2812–20.
64. Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica. 2008;93:775–9.
65. Liso A, Bogliolo A, Freschi V, Martelli MP, Pileri SA, Santodirocco M et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia. 2008;22:1285–9.
66. Ballanti S, Mastrodicasa E, Bolli N, Lotti F, Capolsini I, Berchicci L et al. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nat Clin Pract Oncol. 2007;4:722–5.
67. Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92:519–32.
68. Bolli N, De Marco MF, Martelli MP, Bigerna B, Pucciarini A, Rossi R et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia. 2009;23:501–9.
69. Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia. 2007;21:1099–103.
70. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999–2005.
71. Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M et al. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. Haematologica. 2008;93:1017–24.
72. Falini B, Lenze D, Hasserjian R, Coupland S, Jaehne D, Soupir C et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia. 2007;21:1566–70.
73. Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood. 2006;108:4146–55.
74. Martelli MP, Manes N, Liso A, Pettirossi V, Verducci Galletti B, Bigerna B et al. A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. Leukemia. 2008;22:2285–8.
75. Bolli N, Di Ianni M, Simonetti S, Cerroni L, Liso A, Falini B et al. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy. Lancet Oncol. 2004;5:64–5.
76. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107:4514–23.